December 6, 2018 07:00 AM ESTUpdated 08:08 AM

Disgraced VC Steven Burrill heads to prison with 30-month sentence for fraud, tax evasion

Amber Tong

An indictment on 34 counts of wire fraud, investment adviser fraud, and tax evasion has finally led to prison time for venture capitalist Steven Burrill …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Disgraced VC Steven Burrill heads to prison with 30-month sentence for fraud, tax evasion

Amber Tong

Sign up to read this article for free.

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Dis­graced VC Steven Bur­rill heads to prison with 30-month sen­tence for fraud, tax eva­sion

Amber Tong

Sign up to read this article for free.

more like this

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Disgraced VC Steven Burrill heads to prison with 30-month sentence for fraud, tax evasion

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Soleno’s rare pediatric disease drug faces PDUFA delay by three months